December 1, 2020, Vol 324, No. 21, Pages 2131-2222
Therapy for Early COVID-19A Critical Need
Peter S. Kim, MD; Sarah W. Read, MD, MHS; Anthony S. Fauci, MD
free access has active quiz
JAMA. 2020;324(21):2149-2150. doi:10.1001/jama.2020.22813
In this Viewpoint, Fauci and NIAID colleagues review leading candidates for treatment of mild to moderate coronavirus disease 2019 (COVID-19) to prevent disease progression and longer-term complications, including emerging antiviral drugs, immune-modulating agents, and antibody-based therapies, and the challenges of developing randomized trials to rapidly evaluate the safety and efficacy of each.